Thu, November 18, 2010
Wed, November 17, 2010
Tue, November 16, 2010
Mon, November 15, 2010
Sun, November 14, 2010
Fri, November 12, 2010
Thu, November 11, 2010
Wed, November 10, 2010
Tue, November 9, 2010
Mon, November 8, 2010
Sun, November 7, 2010
Sat, November 6, 2010
Fri, November 5, 2010
Thu, November 4, 2010
Wed, November 3, 2010
Tue, November 2, 2010
Mon, November 1, 2010
Sat, October 30, 2010
Fri, October 29, 2010

Neoprobe 3rd Quarter Business Update Conference Call Invitation

  Copy link into your clipboard //health-fitness.news-articles.net/content/2010/ .. -business-update-conference-call-invitation.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

DUBLIN, Ohio--([ BUSINESS WIRE ])--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today confirmed that it would report its financial results for the third quarter of 2010 on Wednesday, November 10, 2010 before the opening of the financial markets. The announcement will be followed by a business update conference call with the investment community scheduled for later that afternoon on Wednesday, November 10, 2010 at 4:30 PM ET. On the call Neoprobea™s President and CEO, David Bupp, Senior Vice President, Pharmaceutical Research and Clinical Development, Dr. Frederick Cope, and Senior Vice President and CFO, Brent Larson, will provide a business update, review results for the third quarter of 2010 and discuss recent corporate events. The conference call can be accessed as follows:

Conference Call Information
TO PARTICIPATE LIVE: TO LISTEN TO A REPLAY:
Date: November 10, 2010 Available until: November 24, 2010
Time: 4:30 PM ET

Toll-free (U.S.) Dial in #:

877-660-6853

International Dial in #:

201-612-7415

Toll-free (U.S.) Dial in #:

877-407-8033 Replay Passcodes:

International Dial in #:

201-689-8033 Account #: 286
Conference ID #: 360421

About Neoprobe Corporation

Neoprobe Corporation (OTCBB: NEOP) is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScana". Neoprobea™s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobea™s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. [ www.neoprobe.com ].